Akums Drugs and Pharmaceuticals will acquire Oriflame India’s manufacturing facilities in Roorkee and Noida for ₹56 crore. This move marks the pharma company’s entry into the color cosmetics and personal care manufacturing market. The deal, expected to close by August 31, 2026, helps the firm diversify its production base beyond its core pharmaceutical business.
Detailed Coverage
Akums Drugs and Pharmaceuticals has announced a definitive agreement to acquire the manufacturing operations of Oriflame India. The deal is valued at ₹56 crore and will be executed through the company’s wholly-owned subsidiary, Pure and Cure Healthcare Private Limited. The transaction involves taking over two production facilities—one in Roorkee, Uttarakhand, and another in Noida, Uttar Pradesh—along with a warehouse in Noida. The acquisition is currently expected to be completed by August 31, 2026, subject to customary closing conditions.
Strategic Diversification Beyond Pharmaceuticals
For Akums, which has traditionally focused on contract manufacturing for the pharmaceutical industry, this acquisition serves as a platform to enter the personal care and color cosmetics segment. The company management indicated that this move aligns with a broader strategy to reduce reliance on pure-play medicine manufacturing and tap into higher-growth consumer categories. The acquired sites are already equipped to handle a variety of products, including skincare, hair care, and wellness items, in addition to color cosmetics.
Manufacturing and Operational Impact
By acquiring existing facilities, Akums gains immediate access to ready-to-use infrastructure rather than going through the time-intensive process of setting up new manufacturing lines. This approach allows the company to integrate established production expertise and serve a wider array of domestic and international brands. For investors, the success of this expansion will depend on the company’s ability to maintain efficient operations in these new categories and leverage the existing client base transition smoothly.
Financial Context and Market Position
Akums Drugs and Pharmaceuticals operates in the highly competitive Contract Development and Manufacturing Organization (CDMO) space. While the pharmaceutical manufacturing sector is often characterized by stable demand, it also faces pressure from regulatory compliance costs and pricing competition. Moving into the personal care and cosmetics space introduces the company to a different set of market dynamics, where brand demand and consumer trends play a larger role in revenue stability. Investors should monitor how this new vertical affects the company’s overall profit margins and whether the integration of these facilities leads to a meaningful contribution to the bottom line in the coming quarters. The company’s ability to manage the transition and optimize the utilization of these new assets will be the primary monitorable for the next few financial periods.